News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Second-Hand Asbestos Exposure Responsible for Some Mesothelioma Cases
- Lab-on-Bead Offers Potential to Quickly Develop New Treatment for Mesothelioma
- “Rock for Doc” Concert Held to Raise Money for Doctor’s Mesothelioma Treatments
- NY Mesothelioma and Asbestos Attorney Applauds Changes to City’s Building Inspection Oversight
- Mesothelioma Patient Cancer-Free Five Years After Innovative Treatment
- University of Arizona’s Cancer Center Hopes to Become Premier Mesothelioma Treatment Facility in the Southwest
- SBRT, Useful for Treating Mesothelioma, to be Discussed at 2010 ASTRO Conference
- British Man Fights Mesothelioma by Running
- Ogdensburg Receives Grant Money to Demolish Buildings Known to Contain Mesothelioma-Causing Asbestos
- ADI-PEG 20 Shows Promise in Inhibiting Mesothelioma Cancer Cell Growth
Wednesday, February 3, 2010
The most common chemotherapy treatment for malignant pleural mesothelioma is a combination therapy of cisplatin and pemetrexed. This combination is used as a first-line treatment in patients for which resection (surgery) is not an option, as well as in adjuvant chemotherapy treatment after surgery. This combination is effective, yet it can be toxic with a range of side effects including decreased kidney function.
Malignant Peural Mesothelioma (MPM) is a form of lung cancer that is caused by inhaling airborne asbestos fibers and affects the outer lining of the lungs called the mesothelium. While pleural mesothelioma is not classified as a lung cancer according to the medical defintion, the treatments between lung cancer and mesothelioma are often similar. There is no cure for malignant mesothelioma and the treatments that are used to fight the disease are considered aggressive and can be difficult on the patient.
According to a study in the Journal of Clinical Oncology the combination of
carboplatin, as opposed to cisplatin, and pemetrexed is well tolerated in patients with malignant pleural mesotheliom. “Disease control rate, time to disease progression, and overall survival” were similar to those of patients treated with the standard regimen of pemetrexed and cisplatin.
The choice between treatment with cisplatin or carboplatin for mesothelioma
should be discussed with your oncologist. While carboplatin is often better tolerated, the efficacy of cisplatin is slightly better. If kidney function declines while on cisplatin, a switch to carboplatin is reasonable.
Source:
Journal of Clinical Oncology
Labels: mesothelioma, treatments
posted by Nancy Meredith at 8:00 AM
